dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Posição atual:
>
> This Story


Início de uma sessão ou Registo to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

CT Homepage

First ultra high-res CT scan performed on US patient Scanner at UC Davis can image anatomy as small as 150 microns

Trice Imaging connects imaging devices of large chain healthcare provider Aleris Patients and physicians can view images on laptops, cell phones

Industrial hi-res X-ray yields greater insight into child abuse case Identified microscopic injuries that would not have been detected with standard CT

Reducing extravasations in CT contrast-enhanced IV injections Tips and best practices for administering better care

Researchers orchestrate malware attack to expose imaging vulnerabilities Deceived radiologists and AI algorithms into misdiagnoses

House bill would require Medicare to cover CT colonography Supporters say it would improve screening compliance and outcomes

New approach identifies lung cancer patients most likely to respond to chemotherapy Combines radiomics and CT image assessment

BSWH to install Glassbeam's CLEAN blueprint to leverage machine uptime Will include integrated CMMS software by EQ2

Machine learning reduces false positives for lung cancer in low-dose CT False positives occur at rate of 96 percent

Siemens to unveil its SOMATOM go.Top Cardiovascular Edition CT at ACC 19 Ideal for the cardiovascular outpatient setting

Progenics offers Curium exclusive license
to distribute its imaging agent, PyL

Progenics Pharmaceuticals selects Curium as European distributor of PyL

por John R. Fischer , Staff Reporter
Progenics Pharmaceuticals has selected Curium to be the distributor of its PSMA-targeted small molecule PET/CT imaging agent, PyL, in Europe.

The oncology company has granted an exclusive license to Curium to develop, and oversee regulatory approval and commercialization of the tracer, which is currently in Phase 3 development and designed to visualize prostate cancer.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



“Curium is a world-class leader in nuclear medicine and an ideal partner for PyL, with the infrastructure, commercial footprint and experience in prostate cancer to position PyL for success in Europe,” Mark Baker, CEO of Progenics, said in a statement. “This collaboration accelerates development of PyL in this important market, while we focus our internal efforts on advancing our Phase 3 CONDOR trial and laying the groundwork for commercialization in the United States.”

A nuclear medicine manufacturer, Curium recently partnered with RadioMedix to develop and commercialize 64Cu-Dotatate, a tracer with a 12-hour half-life that can be used to identify suspected neuroendocrine tumors during PET exams.

It also expanded its European footprint to 25 sites back in May with the acquisition of PET diagnostics maker, Cyclopharma. The move expanded its French network to 13 radiopharmacies.

The addition of the distribution rights for PyL to the Curium portfolio is a classic example of its initiative to continue growing and expanding its portfolio of nuclear medicine diagnostics, according to Curium CEO Renaud Dehareng.

“PyL has the potential to detect small lesions, offering significant advantages over existing products and others in development,” he said. “We look forward to leveraging our success with F-Choline in prostate cancer to advance the development and commercial uptake of this next-generation product.”

Curium is set to meet with European regulators in the first half of 2019 to determine an agreed-upon regulatory path.

Progenics is entitled to royalties on net sales.

CT Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente a Sua Perceção da Marca
Leilões + Vendas Privadas
Comece
O mais melhor preço
Comprar Equipamento/Peças
Encontre
O preço o mais baixo
Notícia diária
Leia
A notícia a mais atrasada
Diretório
Browse tudo
DOTmed Usuários
Ética no DOTmed
Veja o nosso
Programa das éticas
O ouro parte o programa do vendedor
Receba PH
Pedidos
Programa do negociante do serviço do ouro
Receba RFP/PS
Pedidos
Fornecedores de Healthcare
Veja tudo
Ferramentas de HCP
Trabalhos/Treinamento
Achado/suficiência
Um trabalho
Parts Hunter +EasyPay
Comece as peças
Citações
Certificado recentemente
Vista recentemente
Usuários certificados
Recentemente Rated
Vista recentemente
Usuários certificados
Central Rental
Equipamento do aluguel
Para menos
Vender Equipamentos/Peças
Comece
A maioria de dinheiro
Preste serviços de manutenção ao Forum dos técnicos
Ajuda do achado
E conselho
Simples RFP
Comece o equipamento
Citações
Mostra de comércio virtual
Serviço do achado
Para o equipamento
O acesso e o uso deste local são sujeitos aos termos e às condições do nosso OBSERVAÇÃO LEGAL & OBSERVAÇÃO DA PRIVACIDADE
Propriedade de e proprietário DOTmeda .com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
TODOS OS DIREITOS RESERVADOS